Washington: Greek veterinarian and the chairman and chief executive officer of Pfizer Dr Albert Bourla said on Tuesday that Pfizer is in the final stages of an agreement with India to supply anti-COVID-19 vaccines, observing that the domestically manufactured vaccines would be the backbone of vaccinating the Indian people.
Addressing the 15th edition of the India-US BioPharma & Healthcare Summit being organised by the US-India Chamber of Commerce, Dr Bourla also said that Pfizer has made a specific plan that the mid and low-income countries, which includes India, will receive at least two billion of such doses. “My hope is that very soon we will finalise the approval of the product in India by the Indian health care authorities and the agreement with the government so that we can also start sending vaccines, on our side,” Dr. Bourla said.
The Pfizer CEO said that a significant local manufacturing of vaccines that is happening at the Serum Institute of India will provide the “backbone of vaccinating” the Indian people. “But getting the additional mRNA vaccines from us and also from Moderna will contribute significantly,” he said, adding that the company is confident of producing three billion doses of COVID-19 vaccines and another four billion by next year, making it seven billion in all.
Covid Roundup: Mongolia's Covid-19 cases top one-Lakh-landmark
Pakistan reports major decrease in Covid cases, sees lowest positivity rate in 8 months
Joe Biden Admin to Fall Short of targeted July Vaccination Goal: Official